Moderated by:

Kate Webbley – Team Leader, Metabolism Radiolabelled Sciences at Pharmaron

Kate Webbley graduated from her undergraduate degree in biomolecular and medicinal chemistry at Strathclyde in Glasgow and went on to obtain a postgraduate MSc focusing on drug metabolism and pharmacokinetics at Kings Collage London. She has worked at the Pharmaron Rushden site for 19 years, progressing from research scientist to team leader across various areas from small molecule in vivo, in vitro and in later years moving into the large molecules area.

Speakers:

Rob Webster’s – Vice President, Pharmacokinetics, Dynamics and Drug Metabolism at Pfizer

Rob Webster is Vice President in the Pharmacokinetics, Dynamics, and Drug Metabolism Department at Pfizer in Andover.  He joined the company in 1989.  His main role in Pfizer’s early research is to aid medicinal chemists in designing new drugs that will have good exposure in the body. Rob works in both the early compound discover and later stage development for many classes of drug candidates, including small molecule, proteins, peptides, LNP, GTx, etc.  His research interests over the years have focused on may different areas including biotherapeutics, PK and PD prediction, small molecule discovery, QT prolongation, etc.  Rob earned his BSc. in biochemistry from Liverpool Polytechnic in 1989, after which he went to work in the Pfizer labs in Sandwich, UK, later moving to Pfizers in Massachusetts, USA.  He is an author or coauthor on over 50 research publications.

Thomas Gregson – Associate Director, Radiolabelled Sciences at Pharmaron

Tom Gregson graduated from Sheffield University with a Masters in Chemistry and undertook a PhD at the University of Manchester with Professor Jim Thomas in natural product synthesis. He has worked in radiolabelled synthesis for over 20 years, initially at Sanofi-Aventis and Covance before joining Pharmaron.  As Associate Director at the Cardiff site, he brings extensive experience in radiolabelling of a range of molecules with both Carbon-14 and Tritium.

Stephen Harris – Metabolism Team Leader at Pharmaron

Steve Harris has over 35 years’ experience working within DMPK groups, initially at Roche and Pfizer, working mostly on the pre-clinical development of radiolabelled small molecules.  Since joining Pharmaron in 2010 he led the group responsible for radiolabelled ADME studies with Biologics, ranging from peptides and nucleic acids to recombinant proteins, mAb’s, fusion proteins and ADC’s, until retiring in 2023.  Since then, he has acted as a biologics and imaging consultant.